Cardiovascular and renal outcomes of GLP-1 receptor agonists in type 2 diabetes mellitus: a systematic review and meta-analysis.

Eur Heart J Qual Care Clin OutcomesSep 16, 2026
Clinical ResearchEndocrinologyCardiology

Mushood Ahmed, Tallal Mushtaq Hashmi, Maryam Shahzad et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on cardiovascular outcomes in 83,004 patients with type 2 diabetes mellitus (T2DM). The study found that GLP-1RAs significantly reduced the risk of major adverse cardiovascular events (RR 0.87, 95% CI 0.83-0.92) compared to placebo, supporting their cardioprotective benefits.

Key findings

  • GLP-1RAs reduced the risk of major adverse cardiovascular events (RR 0.87, 95% CI 0.83-0.92).
  • All-cause mortality was reduced with GLP-1RAs (RR 0.89, 95% CI 0.84-0.93).
  • Cardiovascular death risk decreased (RR 0.88, 95% CI 0.81-0.94).
  • Composite renal outcomes improved (RR 0.80, 95% CI 0.73-0.88).

Why it matters

The findings underscore the importance of GLP-1RAs not only for glycemic control but also for their significant cardiovascular and renal protective effects in patients with T2DM, aligning with current clinical guidelines.

Source

PubMed · PMID 42142362

Published in Eur Heart J Qual Care Clin Outcomes. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.